Intercept Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Intercept Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Intercept Pharmaceuticals Inc Strategy Report
- Understand Intercept Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Intercept Pharmaceuticals Inc (Intercept), a subsidiary of Alfasigma SpA, is a biopharmaceutical company that researches, develops, and commercializes treatments for non-viral, progressive liver diseases. It develops products using proprietary bile acid chemistry. The company’s lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor. The company is advancing OCA for the treatment of various other liver diseases. The company harnesses its proprietary bile acid chemistry to develop innovative drugs. It is also advancing INT-787, an FXR agonist with anti-inflammatory and anti-fibrotic effects that can be used in a broad range of diseases. The company has operations in the US, Europe, and Canada. Intercept is headquartered in New York, the US.
Headquarters
United States of America
Address
305 Madison Avenue, Morristown, New Jersey, 07960
Website
www.interceptpharma.com
Telephone
1 646 7471000
No of Employees
341
Industry
Pharmaceuticals and Healthcare
Revenue (2022)
$285.7M
Intercept Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products |
|---|
| - |
| Marketed |
| Ocaliva (Obeticholic Acid): |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In September, the company entered into an agreement to be acquired by Alfasigma S.p.A. |
| 2023 | Regulatory Approval | In May, the company announced that the U.S. Food and Drug Administration granted orphan drug designation for the fixed-dose combination of obeticholic acid (OCA) and bezafibrate for the potential treatment of individuals with primary biliary cholangitis (PBC). |
| 2023 | Others | In March, the company announced FDA Advisory Committee meeting date for obeticholic acid as a treatment for pre-cirrhotic liver fibrosis to be held virtually. |
Competitor Comparison
| Key Parameters | Intercept Pharmaceuticals Inc | Novartis AG | AstraZeneca Plc | Bristol-Myers Squibb Co | Novo Nordisk AS |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United Kingdom | United States of America | Denmark |
| City | Morristown | Basel | Cambridge | Princeton | Bagsvaerd |
| State/Province | New Jersey | - | England | New Jersey | - |
| No. of Employees | 341 | 76,057 | 89,900 | 34,100 | 63,370 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Paolo Fundaro | Chairman | Executive Board | 2015 | 49 |
| Jerome Durso | Chief Executive Officer; Director; President | Executive Board | 2021 | 55 |
| Andrew Saik | Chief Financial Officer | Senior Management | 2021 | 53 |
| Rocco Venezia | Treasurer; Chief Accounting Officer | Senior Management | 2021 | 47 |
| Michelle Berrey | President - Research and Development; Chief Medical Officer | Senior Management | 2021 | 56 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward